Working… Menu

A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus (VC01-103)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04678557
Recruitment Status : Recruiting
First Posted : December 22, 2020
Last Update Posted : March 2, 2021
Information provided by (Responsible Party):

Brief Summary:
VC01-103 will evaluate an experimental combination product, cell replacement therapy intended to provide a functional cure to subjects with Type 1 Diabetes.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Combination Product: VC-01 Combination Product Phase 1 Phase 2

Detailed Description:
This trial will test if VC-01 combination product can be implanted and maintained with safety, tolerability, and efficacy for up to Month 12/Week 52.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: There are two Cohorts in this study design. Cohort 1 (Phase 1) enrolls up to 30 subjects total. After Cohort 1 enrollment is completed, Cohort 2 enrollment then occurs with up to an additional 40 subjects. A total of up to 70 subjects will be enrolled under this Phase 1/2 protocol.
Masking: None (Open Label)
Primary Purpose: Other
Official Title: An Open-Label Phase 1/2 Study to Evaluate the Safety, Engraftment, and Efficacy of VC-01™Combination Product in Subjects With Type 1 Diabetes Mellitus
Actual Study Start Date : June 25, 2019
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : April 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: Sentinel units (aka Cohort 1)
VC-01 Combination Product; Up to ten (10) VC-01 sentinels
Combination Product: VC-01 Combination Product
PEC-01 cells loaded into an Encaptra Drug Delivery System
Other Name: PEC-Encap

Experimental: Dose-finding units (aka Cohort 2)
VC-01 Combination Product; Up to twelve units implanted of which up to nine (9) are VC-01-DF (dose-finding) implants and the rest are VC-01 sentinels
Combination Product: VC-01 Combination Product
PEC-01 cells loaded into an Encaptra Drug Delivery System
Other Name: PEC-Encap

Primary Outcome Measures :
  1. Cohort 1: The percentage of graft cells present at post-implant time points relative to pre-clinical models [ Time Frame: Up to 26 weeks ]
    Assess via histology the potential for functional engraftment of VC-01 combination product

  2. Cohort 2: The change in AUC from baseline to Week 26 in C-peptide during 4-HR MMTT [ Time Frame: To Week 26 ]
    Evaluate the clinical efficacy of VC-01 combination product.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and non-pregnant women
  • Diagnosis of T1DM for a minimum of 3 years.
  • Stable, optimized diabetic regimen
  • Acceptable candidate for implant and explant procedures.
  • Willing and able to comply with protocol requirements.
  • Meet insulin dosing requirements per protocol

Exclusion Criteria:

• Advanced complications associated with diabetes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04678557

Layout table for location contacts
Contact: Clinical Operations 858-207-0500

Layout table for location information
United States, California
AMCR Institute Active, not recruiting
Escondido, California, United States, 92025
Diablo Clinical Research Recruiting
Walnut Creek, California, United States, 94598
Contact: Emily Galdes    925-930-7267 ext 226   
United States, Georgia
Atlanta Diabetes Associates Recruiting
Atlanta, Georgia, United States, 30318
Contact: Study Coordinator    404-355-4393      
United States, Texas
Texas Diabetes & Endocrinology Recruiting
Austin, Texas, United States, 78731
Contact: Study Coordinator    512-458-8400      
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Howard Foyt, MD, PhD ViaCyte, Inc.
Additional Information:
Layout table for additonal information
Responsible Party: ViaCyte Identifier: NCT04678557    
Other Study ID Numbers: VC01-103
First Posted: December 22, 2020    Key Record Dates
Last Update Posted: March 2, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases